How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?

Mod Pathol. 2023 Jul;36(7):100222. doi: 10.1016/j.modpat.2023.100222. Epub 2023 Jun 18.

Authors

Jen-Fan Hang¹, Yu-Cheng Lee²

Affiliations

¹ Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: jfhang@vghtpe.gov.tw.
² Department of Pathology, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.

PMID: 37336120
DOI: 10.1016/j.modpat.2023.100222

No abstract available

Keywords: NTRK fusion; immunohistochemistry; pan-TRK; papillary thyroid carcinoma.

Publication types

Letter
Comment

MeSH terms

Biomarkers, Tumor / genetics
Gene Fusion
Humans
Immunohistochemistry
Neoplasms*
Oncogene Proteins, Fusion / genetics
Receptor, trkA / genetics
Receptor, trkC / genetics
Thyroid Cancer, Papillary / genetics
Thyroid Neoplasms* / genetics

Substances

Receptor, trkA
Receptor, trkC
Oncogene Proteins, Fusion
Biomarkers, Tumor